Eminent Capital Partners is a private equity general partner firm headquartered in Manhattan, NY, United States.
ACT Genomics, an integrated cancer molecular information company that transforms precision cancer care, raised $12.5m in Series B funding.
Tarveda Therapeutics, a biopharma company, raised $38m in Series C funding co-led by Novo A/S and New Enterprise Associates.
Blend Therapeutics, a biopharmaceutical firm focused on treating cancer, has raised $21m in funding from NEA, Flagship Ventures and others.
Read more news concerning Eminent Capital Partners
A sampling of Eminent Capital Partners portfolio companies:
View all of the investments in their portfolio
Registration is fast, free and easy
Already a member?